Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
27 February 2025 - 10:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
(the 'Company')
Publication of Annual Report 2024
The Company has today published on its website www.annualreport.gsk.com its
Annual Report for the year ended 31 December 2024 ('Annual Report
2024').
In compliance with Listing Rule 6.4.1R of the UK Financial Conduct
Authority ('FCA'), the Annual Report 2024 has been submitted to the
FCA's National Storage Mechanism ('NSM') and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
A hard copy version of the Annual Report 2024 and the Notice of
Annual General Meeting 2025 ('AGM Notice') will be sent to those
shareholders who have elected to receive paper communications on or
around 24 March 2025. The AGM Notice will be made available to
shareholders who have not elected to receive paper communications
on the same date.
This announcement is not a substitute for reading the Annual Report
2024 in full.
Additional Information
For the purposes of complying with the FCA's Disclosure Guidance
and Transparency Rules ('DTRs') and the requirements imposed on
issuers through the DTRs, information required to be communicated
with the media in unedited full text was included in the Annual
Report 2024. The Annual Report 2024 was submitted to the NSM and
will shortly be available for inspection. It is also available on
the Company's website as noted above.
This announcement is made in accordance with DTR
6.3.5R(1A).
V A Whyte
Company Secretary
27 February 2025
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
27, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Feb 2025 to Mar 2025
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Mar 2025
